You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
481 A CXCR4 partial agonist TFF2-MSA sensitized advanced gastric cancer to PD-1 blockade by systematically reducing PMN-MDSC accumulation, immunosuppression, and generation in bone marrow

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023136011
Dec 20237306
Jan 20244402
Feb 20245004
Mar 20245801
Apr 20244602
May 20241808
Jun 20242002
Jul 20242208
Aug 20241603
Sep 20241800
Oct 20241007
Nov 20243804
Dec 20241209
Jan 20252005
Feb 20251208
Mar 20250011
Apr 2025104
May 2025008
Jun 2025003
Total5940106